2011
Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials)
Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, Lansky AJ, Stone GW. Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). The American Journal Of Cardiology 2011, 108: 918-923. PMID: 21764028, DOI: 10.1016/j.amjcard.2011.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCoronary AngiographyCoronary CirculationCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPredictive Value of TestsRegional Blood FlowVascular PatencyConceptsTIMI grade 3 flowGrade 3 flowFinal TIMI grade 3 flowST-segment elevation myocardial infarctionElevation myocardial infarctionIndependent predictorsMyocardial infarctionPre-percutaneous coronary intervention (PCI) thrombolysisMyocardial Infarction (TIMI) grade 3 flowAcute Myocardial Infarction trialExtensive coronary diseaseLate Angioplasty ComplicationsMyocardial Infarction trialInfarct artery patencyAcute myocardial infarctionSignificant independent predictorsHigh-risk characteristicsAngioplasty complicationsBaseline TIMIControlled AbciximabHarmonizing OutcomesInitial angiographyCause mortalityPrimary PCIArtery patency
2006
Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial)
Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O’Neill W, Lansky AJ, Griffin JJ, Investigators C. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2006, 98: 331-337. PMID: 16860018, DOI: 10.1016/j.amjcard.2006.01.102.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAnticoagulantsBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexStentsStroke VolumeSurvival RateTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIMyocardial Infarction (TIMI) grade 3 flowIschemic target vessel revascularizationGrade 3 flowOutcomes of patientsTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationAcute MICoronary interventionMyocardial infarctionAcute ST-segment elevation myocardial infarctionSegment elevation acute myocardial infarctionMajor adverse cardiac eventsElevation acute myocardial infarctionOngoing chest painSimilar late mortalityAdverse cardiac eventsElevation myocardial infarctionST-segment elevationAcute myocardial infarctionHigher ejection fractionPostprocedural Thrombolysis
2003
Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)
Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, Stone GW. Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). The American Journal Of Cardiology 2003, 92: 1091-1094. PMID: 14583362, DOI: 10.1016/j.amjcard.2003.06.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCross-Over StudiesDrug Administration ScheduleFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsIntraoperative ComplicationsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesTreatment FailureConceptsAcute myocardial infarctionMyocardial infarctionGlycoprotein IIb/IIIa receptor inhibitorsUnsuccessful primary percutaneous coronary interventionIIb/IIIa receptor inhibitorsMyocardial Infarction (TIMI) grade 3 flowPrimary percutaneous coronary interventionGrade 3 flowPercutaneous coronary interventionSuboptimal angioplasty resultsAbciximab administrationCADILLAC trialIschemic complicationsControl patientsCoronary interventionProcedural complicationsAngioplasty resultsReceptor inhibitorsPrimary interventionAbciximabPatientsComplicationsInfarctionLower ratesIntervention
2001
Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial)
Brodie B, Stone G, Morice M, Cox D, Garcia E, Mattos L, Boura J, O’Neill W, Stuckey T, Milks S, Lansky A, Grines C, Group F. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). The American Journal Of Cardiology 2001, 88: 1085-1090. PMID: 11703949, DOI: 10.1016/s0002-9149(01)02039-2.Peer-Reviewed Original ResearchConceptsPrimary percutaneous transluminal coronary angioplastyPrimary PTCAAcute myocardial infarctionCardiogenic shockCoronary angioplastyMyocardial infarctionMyocardial Infarction (TIMI) grade 3 flowPercutaneous transluminal coronary angioplastyInfarct artery reocclusionStent-PAMI trialGrade 3 flowPrimary coronary angioplastyTransluminal coronary angioplastyTriage of patientsArtery reocclusionMortality benefitSurvival benefitEjection fractionLate reperfusionClinical outcomesMyocardial salvageThrombolytic therapyReperfusionPatientsLack of correlation